Asset 2 Conferences
Cancer Biology

Tumor Heterogeneity, Plasticity and Therapy (virtual edition)

5-6 May 2021, Virtual edition
Tumor Heterogeneity, Plasticity and Therapy - campaign visual

Tumor Heterogeneity, Plasticity and Therapy (virtual edition)

Tumor Heterogeneity, Plasticity and Therapy (virtual edition)
Keep me postedAdd to calendar

We are pleased to announce the first edition of the VIB Conference ‘Tumor heterogeneity, plasticity and therapy’. This will be a virtual conference.

Tumors are complex and evolving ecosystems composed of a wide variety of cell types, in addition to the cancer cells themselves. Increasing evidence indicates that the bi-directional interplay between tumor cells and their tumor microenvironment shape tumor evolution and therapy resistance.

Within a tumor, many cancer cells differ from each at the (epi-)genomic, transcriptional and proteomic level, as well as phenotypically and functionally. Tumor heterogeneity represents a major hurdle for therapy, which may only target a subset of tumor cells. In addition, cancer cell plasticity permits rapidly adaption to therapeutics and development of tolerance and resistance, presenting additional challenges for both targeted and immunotherapies.

During this conference a range of world leaders from academia and industry will discuss the latest developments in basic research, translational and clinical research and therapeutic avenues, in the following sessions:

  • Plasticity in initiation, progression and metastasis
  • Heterogeneity and reprogramming of the tumor immune- and microenvironment
  • Adaptation and resistance to immunotherapies
  • Adaptation and resistance to targeted therapies


Time zone and VODs
The time zone for the schedule is CET Brussels. VODs of the presentations (with permission of the speakers) will be made available for the attendees for a period of 4 weeks.

Share

Confirmed speakers

Johanna Joyce
Joyce Johanna - profile picture
Johanna Joyce

Johanna Joyce

Department of Oncology, University of Lausanne, Ludwig Institute for Cancer Research, CH
Erika Pearce
Pearce Erika - profile picture
Erika Pearce

Erika Pearce

Johns Hopkins University & Bloomberg-Kimmel Institute for Cancer Immunotherapy, US
Leila Akkari
Akkari Leila - profile picture
Leila Akkari

Leila Akkari

Division of Tumor Biology & Immunology, Oncode Institute. Netherlands Cancer Institute (NKI), NL
Mark Dawson
Dawson Mark - profile picture
Mark Dawson

Mark Dawson

Sir Peter MacCallum Department of Oncology & Centre for Cancer Research, University of Melbourne, AU
Zemin Zhang
Zhang Zemin - profile picture
Zemin Zhang

Zemin Zhang

BIOPIC, College of Life Sciences, and Beijing Advanced Innovation Center for Genomics, Peking University, CN

Program

Day 1 - Wednesday, 05 May, 2021

11:00
12:00
Welcome coffee
12:00
12:10
Welcome
Session 1 - Plasticity & initiation/progression and metastasis (including CTCs)
12:10
12:40
Small Cell Lung Cancer and Vasculogenic Mimicry - a route to metastasis

Caroline Dive

CRUK Manchester Institute, The University of Manchester, UK
12:40
13:10
Dissecting the metastatic microenvironment
13:10
13:20
Mitochondrial translation drives metabolic reprogramming required for metastasis

Sylvain Delaunay

German Cancer Research Center – Deutsches Krebsforschungszentrum (DKFZ), DE
Selected from abstracts
13:20
13:30
Short break
13:30
14:00
Metabolic intra-tumor heterogeneity driving metastasis formation
14:00
14:30
Targeting Regenerative Plasticity in Metastasis
14:30
14:40
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
14:40
14:45
Company talk: How VectorBuilder can support your oncology research

Justin Mirus

Senior Business Development Manager, Central Europe, VectorBuilder GmbH, DE
Sponsored talk
14:45
15:15
Meet the speaker session 1
14:45
15:15
Coffee Break and Networking
15:15
16:00
Virtual Poster and Booth Session: Plasticity & Heterogeneity
Session 2 - Heterogeneity and reprogramming of the Tumor (immune) microenvironment
16:00
16:30
Distinct properties of tumor-infiltrating immune cells across multiple cancer types

Zemin Zhang

BIOPIC, College of Life Sciences, and Beijing Advanced Innovation Center for Genomics, Peking University, CN
16:30
17:00
Exploring and Exploiting the Tumor Microenvironment

Johanna Joyce

Department of Oncology, University of Lausanne, Ludwig Institute for Cancer Research, CH
17:00
17:10
Delayed immune pressure in never-smoker lung cancer sculpts tumour evolution

Clare E Weeden

The Walter and Eliza Hall Institute of Medical Research, Parkville, AU; Department of Medical Biology, University of Melbourne, Parkville, AU
Selected from abstracts
17:10
17:20
Short break
17:20
17:50
Neuronal activity promotes the progression of glial malignancies
17:50
18:20
Immune contexture and tumor evolution in the era of immunotherapy

Jérôme Galon

INSERM & Laboratory of Integrative Cancer Immunology, Sorbonne Universite, FR
18:20
18:30
Mass spectrometry imaging for the study of intra-tumor heterogeneity
18:30
19:00
Closing talk
Epigenetic influence of our (fatty) diet on metastatic-initiating cells
19:00
19:30
Meet the speaker session 2
19:30
20:30
Networking

Day 2 - Thursday, 06 May, 2021

11:00
12:00
Welcome coffee
Session 3 - Adaptation and Resistance to immuno-therapies
12:00
12:30
Cancer evolution, immune evasion and metastasis
12:30
13:00
Epigenetic mechanisms of malignant clonal dominance and immune evasion

Mark Dawson

Sir Peter MacCallum Department of Oncology & Centre for Cancer Research, University of Melbourne, AU
13:00
13:10
A Single-cell Map of the Dynamic Changes during Immune-checkpoint Blockade in Early Breast Cancer
13:10
13:20
Immunological response and resistance of human cancers to PD-1 blockade

Lisanne Roelofsen

Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, NL
Selected from abstracts
13:20
13:30
Short break
13:30
14:00
Primary and secondary resistance to cancer immunotherapy
14:00
14:30
Harnessing the potential of myeloid cells in brain and liver cancer treatment: a matter of genetics, time and combination

Leila Akkari

Division of Tumor Biology & Immunology, Oncode Institute. Netherlands Cancer Institute (NKI), NL
14:30
14:40
Identification of Chitinase 3-like 1 as a soluble immune checkpoint paralyzing the cytotoxic granule machinery
14:40
14:45
Company talk: Accelerating (immuno)oncology research and therapies

Matthieu Pesant

Senior Market Strategy Manager, Gene & Cell Therapy, Takara Bio Europe, FR
Sponsored talk
14:45
15:15
Meet the speaker session 3
14:45
15:15
Coffee Break and Networking
15:15
16:00
Virtual Poster and Booth Session: Immunotherapies & Targeted therapies
Session 4 - Adaptation and Resistance to targeted therapies
16:00
16:30
Understanding the molecular evolution of tumors during therapy
16:30
17:00
Starvation and pseudo-starvation as drivers of phenotypic plasticity

Colin Goding

Ludwig Institute for Cancer Research, University of Oxford, UK
17:00
17:10
THEM6-mediated lipid remodelling sustains stress resistance in cancer
17:10
17:20
Short break
17:20
17:50
Tumor cell plasticity as a challenge for targeted therapies in colorectal cancer
17:50
18:20
Heterogeneity and plasticity in head and neck cancer
18:20
18:30
Therapy-induced epigenetic inactivation of MCT1 renders tumor cells vulnerable for MCT4 inhibition

Catherine Vander Linden

Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, BE
Selected from abstracts
Closing Talk
18:30
19:00
Phosphatidylinositol saturation drives CD8+ effector T cell signaling and anti-tumor function

Erika Pearce

Johns Hopkins University & Bloomberg-Kimmel Institute for Cancer Immunotherapy, US
19:00
19:10
Closing remarks & Nature Poster Prize announcement
19:10
19:40
Meet the speaker session 4

Organizing committee

Abstracts

The full list of abstracts will be available on 26-04-2021 until 20-05-2021
This list will only be available for registered attendees of the event.

Attendees

The full list of attendees will be available on 26-04-2021 until 20-05-2021
This list will only be available for registered attendees of the event.